Lucentis treats age-related macular degeneration, a disease seen regularly in older adults that can cause loss of sight. Novartis and Roche are partners for the drug, as Roche offers it in the United States and Novartis offers it in Europe.
Avastin, an older and considerably less costly cancer treatment, is frequently repackaged by physicians to treat AMD, according to the report. A vial of Lucentis cost about $1,380 in France, while a vial of Avastin costs $35 to $45.
Katie Adams –
Friday, September 11th, 2020
” Novartis is very dissatisfied by the outcome of the decision and highly refutes the allegations … regarding alleged anti-competitive practices,” a Novartis spokesperson told STAT. “Novartis securely thinks the business has actually acted properly and in compliance with all suitable policies. Novartis believes that this decision relies on a gross misinterpretation of the realities and a distortion of previous case law that is not planned to cover the situation in this case.”.
Avastin has not been approved to deal with AMD, but a 2012 National Institutes of Health study found it to be simply as efficient as Lucentis in treating AMD and a 2014 analysis concluded Avastin did not produce any increased dangers or adverse effects in patients.
© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this material? View our policies by click on this link.
” Novartis is really disappointed by the outcome of the decision and highly refutes the allegations … relating to alleged anti-competitive practices,” a Novartis representative told STAT. “Novartis firmly believes the company has acted properly and in compliance with all applicable regulations. Novartis believes that this decision relies on a gross misinterpretation of the realities and a distortion of previous case law that is not intended to cover the circumstance in this case.”.
More posts on drug store:8 requirements pharmacists need to fulfill to administer COVID-19 vaccinesAHA to HHS: Stop drugmakers violent strategies over 340B discountsCVS expands COVID-19 testing to kids 12 and older.
A Roche representative told STAT, “we respectfully disagree with and are dissatisfied by the choice made by the competitors authority.
Novartis and Roche have been fined a collective $528 million by Frances anti-trust regulator for apparently conspiring to promote the pricey eye disease treatment Lucentis over a less expensive drug, according to STAT.
A Roche representative told STAT, “we respectfully disagree with and are disappointed by the decision made by the competitors authority. Roche showed the best interest of clients and their security in mind and in compliance with the policies set out by the health authorities. We stand behind our actions and will appeal this choice.”.
The French federal government provided the fine because of Novartis and Roches supposed scheme to hawk Lucentis at the expenditure of Avastin, saying the companies were overemphasizing risks related to Avastin without due proof. Novartis was fined about $457 million, and Roche was fined about $71 million.